Your browser doesn't support javascript.
loading
Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck.
Biete Solà, A; Marruecos Querol, J; Calvo Manuel, F A; Verger Fransoy, E; Rovirosa Casino, A; Grau de Castro, J J; de Las Heras González, M; Ramos Aguerri, A; Palacios Eito, A; Veiras Candal, C; Solano López, Maria V.
Afiliação
  • Biete Solà A; Servicio de Oncología Radioterápica, Institut Clínic de Malaties Hemato-Oncològiques (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. abiete@clinic.ub.es
Clin Transl Oncol ; 9(4): 244-50, 2007 Apr.
Article em En | MEDLINE | ID: mdl-17462977
INTRODUCTION: Standard fractionation radiation therapy (RT) combined with concomitant chemotherapy (CT) based on cisplatin schemes is actually the standard treatment for locally advanced non-resectable squamous cell carcinoma of head and neck (SCCHN). The appearance of taxoids has introduced a new kind of treatment with high antitumoral power. The aim of this study is to add more information about the role of this new approach. MATERIALS AND METHODS: Twenty-six patients with locally advanced non-resectable SCCHN were recruited at six institutions in Spain, between January 2001 and January 2003. Docetaxel was administered weekly, for 6 weeks, concurrently with RT. RESULTS: The mean total delivered dose of RT was 70'2 Gy (range 64-74 Gy). The median and mean duration of time were 63 days and 61 days (range 49-103 days) respectively. After a median time control of 19 months (range 3.3-42.2 months), the response rate was 83.4%. The median time to local progression was 16.4 months (95% confidence interval [CI]=4.4-28.4 months). The median survival time was 26.9 months, with one- and two-year overall survival of 66.9% (95% CI=48.1-85.7%) and 57.5% (95% CI=37.3-77.7%) respectively. The median duration time response was 15.1 months (95% CI=3.7-26.5 months). The median time until treatment failure was 9.4 months (95% CI=4.7-14.1). Incidence of grade III-IV mucositis was 88%, neutropenia 72% and skin toxicity 92% (24% grade III-IV). The incidence of severe late toxicity (grade III and IV) due to RT/CT was 31.4%. CONCLUSIONS: Although therapeutics results are equivalent to cisplatin schemes of concurrent CT-RT, mucositis and cutaneous toxicity registered in this trial must be considered as limiting factors to application of this new approach.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Taxoides / Neoplasias de Cabeça e Pescoço Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2007 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Taxoides / Neoplasias de Cabeça e Pescoço Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2007 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália